Eli Lilly: From Sell To Buy In 90 Days, Here's What Changed My Mind [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
LLY's acquisition of Kelonia and Orna Therapeutics positions it at the forefront of in vivo CAR-T therapies, targeting major market expansion. The weight loss franchise drives 56% of LLY revenue but faces pricing, legal, and regulatory risks; monitoring volume vs. price dynamics is critical. Despite a premium valuation (P/E 40), LLY's growth trajectory and pipeline justify consideration alongside Novo Nordisk for portfolio inclusion. JHVEPhoto/iStock Editorial via Getty Images Introduction Eli Lilly and Company ( LLY ) has dropped over 13% since I last rated it a Sell back in January , and with the firm's incoming quarter as well as the just-announced deal This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in LLY over the next 72 hours. I wrote this
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Here's Why Agios Pharmaceuticals Crashed 23% Today [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk Eyes Rare Disease Growth As Etavopivat Phase 3 Succeeds [Yahoo! Finance]Yahoo! Finance
- Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal [Yahoo! Finance]Yahoo! Finance
- Beyond GLP-1Rs: emerging targets poised to gain share of obesity market [Yahoo! Finance]Yahoo! Finance
- Agios Pharmaceuticals stock tumbles 25% after Novo data [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/13/26 - Form 6-K
- NVO's page on the SEC website